← Leaderboards
Gregory G Burrows
Oregon Health And Science University
$6,927,254
Attributed
$6,927,254
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $757.5K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$6,927,254 · 5
By mechanism
R01$6,072,991 · 3
R42$751,424 · 1
R41$102,839 · 1
Top collaborators
No co-investigators on record.
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Catherine W Morgans$12,470,542
Others in their field
Top investigators on “Mhc Class Ii Antigen”
- Kent J. Weinhold · Duke University$40,222,851
- Stephen S. Rich · University Of Alabama At Birmingham$26,347,668
- David I Watkins · George Washington University$26,056,842
- John Altman · Emory University$22,835,835
- Hidde L Ploegh · Boston Children'S Hospital$17,642,651
- Emil R Unanue · Washington University$16,119,744
Research focus
Mhc Class Ii AntigenT LymphocyteLeukocyte Activation /TransformationT Cell ReceptorMultiple SclerosisLigandsReceptor BindingPeptidesDrug Design /Synthesis /ProductionBinding (Molecular Function)BaseMouse ModelPhenotypeLeadAutoimmune DisorderComplexEncephalomyelitisAutoimmune DiseasesExperimental Autoimmune EncephalomyelitisCellsIn VitroIn VivoCd4 Positive T LymphocytesCytokine
Grant awards (21)
Novel MHC Class II Constructs For Treatment of EAE$363,066
R01 · FY2010 · AI · contact PI
Novel MHC Class II Constructs For Treatment of EAE$366,733
R01 · FY2009 · AI · contact PI
Novel MHC Class II Constructs For Treatment of EAE$366,733
R01 · FY2008 · AI · contact PI
HLA-DQ-derived RTLs for Treatment of Celiac Disease$376,680
R42 · FY2007 · DK · contact PI
Novel MHC Class II Constructs For Treatment of EAE$373,329
R01 · FY2007 · AI · contact PI
Novel MHC Class II Constructs For Treatment of EAE$382,709
R01 · FY2006 · AI · contact PI
HLA-DQ-derived RTLs for Treatment of Celiac Disease$374,744
R42 · FY2006 · DK · contact PI
Human MHC Class II Constructs For Autoimmume Therapy$352,500
R01 · FY2005 · NS
Human MHC Class II Constructs For Autoimmume Therapy$352,500
R01 · FY2004 · NS
HLA-DQ-derived RTLs for Treatment of Celiac Disease$102,839
R41 · FY2004 · DK
Human MHC Class II Constructs For Autoimmume Therapy$352,500
R01 · FY2003 · NS
NOVEL MHC CLASS II CONSTRUCTS FOR TREATMENTS OF CBD$345,126
R01 · FY2003 · ES
NOVEL MHC CLASS II CONSTRUCTS FOR TREATMENT OF EAE$291,767
R01 · FY2003 · AI
NOVEL MHC CLASS II CONSTRUCTS FOR TREATMENTS OF CBD$346,014
R01 · FY2002 · ES
Human MHC Class II Constructs For Autoimmume Therapy$334,442
R01 · FY2002 · NS
NOVEL MHC CLASS II CONSTRUCTS FOR TREATMENT OF EAE$265,757
R01 · FY2002 · AI
NOVEL MHC CLASS II CONSTRUCTS FOR TREATMENTS OF CBD$346,956
R01 · FY2001 · ES
Human MHC Class II Constructs For Autoimmume Therapy$334,504
R01 · FY2001 · NS
NOVEL MHC CLASS II CONSTRUCTS FOR TREATMENT OF EAE$275,019
R01 · FY2001 · AI
NOVEL MHC CLASS II CONSTRUCTS FOR TREATMENTS OF CBD$356,326
R01 · FY2000 · ES
NOVEL MHC CLASS II CONSTRUCTS FOR TREATMENT OF EAE$267,010
R01 · FY2000 · AI